(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Lung transplantation remains a vital option for advanced IPF, with increasing transplant numbers and evolving allocation strategies. Idiopathic pulmonary fibrosis (IPF) is characterized by a ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

The term “progressive pulmonary fibrosis” or “PPF” is generally used to describe progressive lung fibrosis in an individual with an interstitial lung disease (ILD) other than idiopathic ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

Inc. The partnership aims to discover antibody therapeutics for idiopathic pulmonary fibrosis (IPF), a serious lung condition. This agreement entails Surrozen providing antibody discovery services ...

Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology ...

Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi ...

Needham analyst Michael Matson reiterated a Buy rating on Veracyte (VCYT – Research Report) today and set a price target of $44.00.